Beta Nerve Growth Factor – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Beta Nerve Growth Factor (Beta NGF or NGF)- Pipeline Review, H2 2019’, provides in depth analysis on Beta Nerve Growth Factor (Beta NGF or NGF) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders and Immunology under development targeting Beta Nerve Growth Factor (Beta NGF or NGF).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)

– The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects

– The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“AstraZeneca Plc

Fujimoto Pharmaceutical Corp

MimeTech Srl

Pfizer Inc

Regeneron Pharmaceuticals Inc

Serometrix LLC

Staidson BioPharma Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Beta Nerve Growth Factor (Beta NGF or NGF) - Overview

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Fujimoto Pharmaceutical Corp

MedImmune LLC

MimeTech Srl

Pfizer Inc

Regeneron Pharmaceuticals Inc

Serometrix LLC

Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles

ASP-6294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7352 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NGF for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products

Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products

Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones

Featured News & Press Releases

Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints

Jul 20, 2018: Pfizer and Eli Lilly report positive results from Phase III tanezumab

Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis

Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs

May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain

Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors

Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug

Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program

Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab

May 12, 2010: Regeneron Provides Initial Data On REGN475

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AstraZeneca Plc, H2 2019

Pipeline by Fujimoto Pharmaceutical Corp, H2 2019

Pipeline by MimeTech Srl, H2 2019

Pipeline by Pfizer Inc, H2 2019

Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Pipeline by Serometrix LLC, H2 2019

Pipeline by Staidson BioPharma Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports